Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer

NCT05081024 is registered in ClinicalTrials.gov with OHSU Knight Cancer Institute as lead sponsor.

NCT NCT05081024
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05081024 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer
Lead sponsor
OHSU Knight Cancer Institute
Phase
Observational
Overall status
Recruiting
Start date
September 3, 2021
Completion date
September 3, 2027
Enrollment
50 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

rectal adenocarcinoma, stage ii rectal cancer ajcc v8, stage iia rectal cancer ajcc v8, stage iib rectal cancer ajcc v8, stage iic rectal cancer ajcc v8, stage iii rectal cancer ajcc v8, stage iiia rectal cancer ajcc v8, stage iiib rectal cancer ajcc v8, stage iiic rectal cancer ajcc v8